Global Bio-Absorbable Stent Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Bio-Absorbable Stent Market Analysis

The bio-absorbable stent market has experienced significant advancements driven by innovative materials and precision manufacturing. The latest technologies, such as drug-eluting bioresorbable stents, use polymers such as polylactic acid (PLA) for controlled drug release to prevent restenosis. Advanced imaging techniques, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), are enhancing stent placement accuracy and monitoring.

3D printing has revolutionized stent prototyping, enabling customized designs that optimize biodegradability and mechanical strength. Moreover, hybrid bioresorbable stents incorporating magnesium alloys provide better radial support and rapid absorption. AI-driven analytics are utilized for patient-specific stent selection and procedural planning, enhancing outcomes.

The usage of bio-absorbable stents is growing due to their ability to minimize long-term complications, such as inflammation and thrombosis, compared to traditional metal stents. They are increasingly employed in treating coronary artery disease, particularly in younger patients, to restore natural vascular function post-absorption.

Market growth is fueled by rising cardiovascular disease prevalence, technological advancements, and government initiatives supporting minimally invasive solutions. Emerging markets, particularly in Asia-Pacific, present lucrative opportunities due to increasing healthcare investments and patient awareness.

Bio-Absorbable Stent Market Size

The global bio-absorbable stent market size was valued at USD 510.89 million in 2024 and is projected to reach USD 1,148.82 million by 2032, with a CAGR of 10.66% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Bio-Absorbable Stent Market Trends

“Increasing Adoption of Drug-Eluting Bio-Absorbable Stents”

A key trend in the bio-absorbable stent market is the growing preference for drug-eluting bio-absorbable stents. These stents are designed to release therapeutic agents, reducing the risk of restenosis while gradually dissolving after serving their purpose. Their ability to improve vascular healing and avoid long-term complications associated with permanent stents has driven their adoption. For instance, Abbott’s Absorb GT1 Bioresorbable Vascular Scaffold System has gained significant attention for offering drug-eluting properties alongside complete absorption by the body over time. This trend aligns with the broader shift toward advanced, patient-centered medical technologies, bolstering market growth, especially in regions with high incidences of coronary artery disease.

Report Scope and Bio-Absorbable Stent Market Segmentation        

Bio-Absorbable Stent Market Definition

A bio-absorbable stent is a medical device designed to open blocked or narrowed arteries, primarily in cardiovascular treatments, and then naturally dissolve in the body over time. Made from materials like polylactic acid or magnesium alloys, these stents support the artery during healing, reducing the risk of long-term complications associated with permanent metallic stents, such as inflammation or restenosis. Bio-absorbable stents degrade within months to years, depending on their composition, leaving no permanent foreign material. They are particularly beneficial for younger patients or those needing future interventions, offering improved flexibility and reducing the need for prolonged antiplatelet therapy.

Bio-Absorbable Stent Market Dynamics

Drivers

• Growing Prevalence of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases, particularly coronary artery disease (CAD), is a significant driver for the bio-absorbable stent market. Globally, CAD remains a leading cause of mortality, with over 17.9 million deaths annually as per WHO data. Bio-absorbable stents offer a revolutionary solution by providing temporary arterial support and gradually dissolving, reducing the risks of long-term complications like restenosis and thrombosis. For instance, India witnessed a notable rise in CAD cases, spurring demand for advanced treatment options. Hospitals now prefer bio-absorbable stents over traditional metal stents to improve patient outcomes and minimize post-surgery interventions, further propelling market adoption.

• Patient Preference for Minimally Invasive Procedures

The demand for minimally invasive procedures has significantly boosted the adoption of bio-absorbable stents in cardiovascular treatments. These stents offer the advantage of dissolving after providing temporary vascular support, reducing the risk of long-term complications like thrombosis and inflammation. Patients increasingly prefer these advanced options as they minimize post-procedure discomfort and recovery time, enhancing overall satisfaction. For instance, in March 2021, Meril Life Sciences launched its indigenously developed MeRes100, a bioresorbable scaffold stent. The MeRes100 is a thin-struct bioresorbable stent designed as an alternative to traditional metallic stents. This innovative product offers a promising treatment option by gradually dissolving within the body, reducing long-term complications and the need for further interventions, while still providing adequate support during the healing process for patients with coronary artery disease.

Opportunities

• Preference for Biocompatible Materials

The growing preference for biocompatible materials in stent manufacturing is creating significant opportunities in the bio-absorbable stent market. These materials, such as polylactic acid and magnesium alloys, promote natural healing while minimizing the risk of inflammatory responses or allergic reactions. For instance, in October 2021, Boston Scientific Corporation unveiled positive results for its Eluvia Drug-Eluting Vascular Stent System at the Vascular InterVentional Advances conference in Las Vegas. The stent system demonstrated impressive clinical outcomes, with higher sustained clinical improvement and superior primary patency rates. This late-breaking trial presentation highlighted the effectiveness of Eluvia in providing long-term vascular support, making it a leading option for treating peripheral artery disease with promising patient outcomes. This trend encourages manufacturers to innovate biocompatible solutions, enhancing market growth while meeting rising demand for safer cardiovascular treatments.

• Initiatives for Improved Cardiovascular Care

Government and non-government programs focusing on cardiovascular disease (CVD) management create significant opportunities in the bio-absorbable stent market. Initiatives like the World Heart Federation’s “Global Hearts Program” aim to reduce the global burden of heart diseases through prevention and treatment strategies. In addition, national campaigns, such as the Million Hearts initiative in the U.S., promote early diagnosis and advanced treatments for CVD. These programs drive healthcare systems to adopt innovative solutions, including bio-absorbable stents, to enhance patient outcomes. Such efforts encourage funding, awareness, and regulatory support, enabling broader adoption of these stents in both developed and emerging markets.

Restraints/Challenges

• Risk of Stent Fracture

The risk of stent fracture significantly hinders the bio-absorbable stent market. Bio-absorbable stents are designed to gradually dissolve in the body, but their material integrity may be compromised over time, leading to potential fracture during or after implantation. This can cause serious complications such as restenosis (re-narrowing of the artery), thrombosis (blood clot formation), or other severe cardiovascular issues. The lack of sufficient long-term data on their stability and the possibility of fractures deter both healthcare professionals and patients from opting for these stents. These concerns, combined with the potential for adverse events, have slowed the adoption of bio-absorbable stents, restricting their growth in the market.  

• Complex Implantation Process

The implantation process for bio-absorbable stents presents a significant challenge due to its technical complexity. Different from conventional metallic stents, bio-absorbable stents require advanced surgical techniques and greater precision during implantation. This increased complexity can make the procedure more time-consuming and demanding for healthcare professionals, limiting its widespread adoption. In addition, the learning curve associated with mastering the implantation process can discourage many physicians from using bio-absorbable stents. Inadequate expertise or technical errors during implantation may lead to complications, increasing the risk for patients. As a result, the intricacies of the procedure contribute to the market’s restraint, hindering the widespread use of bio-absorbable stents in clinical practice.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Bio-Absorbable Stent Market Scope

The market is segmented on the basis of material, product, absorption rate, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Material

• Bioresorbable Polymer-Based Stents
  • PGA
  • PLA
  • Co-Polymer
• Bioresorbable Metallic Stents
• Bioresorbable Natural Material-Based Stents

 Product

• Coronary Stents
• Peripheral Stents
• Stent-Related Implants

 Absorption Rate

• Slow-Absorption Stents
• Fast-Absorption Stents

 Application

• Coronary Artery Disease
• Peripheral Artery Disease

 End User

• Hospitals
• Cardiac Centers
• Specially Clinics/ Clinics
• Others

Bio-Absorbable Stent Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, material, product, absorption rate, application and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

Europe is expected to dominate the bio-absorbable stent market due to the growing focus on research and development within the region. Increasing investments in healthcare innovation and advancements in medical technologies are driving the development of bioresorbable stents. Leading research institutions and hospitals are conducting trials to enhance the effectiveness and safety of these stents.

Asia-Pacific is expected to witness significant growth in the bio-absorbable stent market due to the increasing prevalence of cardiovascular diseases (CAD and PAD), along with a large patient pool in the region. Rising healthcare investments, improved medical infrastructure, and growing awareness of advanced stenting technologies further fuel the market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Bio-Absorbable Stent Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Bio-Absorbable Stent Market Leaders Operating in the Market Are:

• Abbott (U.S.)
• REVA Medical, Inc. (U.S.)
• Elixir Medical Corporation (U.S.)
• KYOTO MEDICAL PLANNING Co., Ltd. (Japan)
• BIOTRONIK (Germany)
• Amaranth Medical, Inc. (U.S.)
• Arterial Remodeling Technologies (France)
• Meril Life Sciences Pvt. Ltd. (India)
• Arterius (U.K.)
• Boston Scientific Corporation (U.S.)
• 480 Biomedical, Inc. (U.S.)
• S3V Vascular Technologies (France)
• QualiMed (Germany)
• OrbusNeich (Hong Kong)
• Medtronic (Ireland)
• STENTYS SA (France)
• Terumo Corporation (Japan)
• MicroPort Scientific Corporation (China)
• BD (U.S.)
• B. Braun Melsungen AG (Germany)

Latest Developments in Bio-Absorbable Stent Market

• In April 2023, BIOTRONIK announced the commercial launch of its Orsiro Mission Drug-eluting stent system in Canada, following its approval by Health Canada. This advanced system aims to enhance coronary luminal diameter in patients suffering from diabetes and other diseases. BIOTRONIK is replacing the original Orsiro system with this latest generation, offering improved performance and therapeutic options for patients with coronary artery disease
• In March 2022, S3V Vascular Technologies, a prominent medical device firm, revealed plans to invest INR 250 crore to build a state-of-the-art stent manufacturing facility at Telangana Medical Devices Park, near Hyderabad. The facility aims to enhance production capabilities for stents, which are crucial for cardiovascular procedures. This move is part of the company's strategy to meet the growing demand for high-quality, locally manufactured medical devices in India
• In February 2022, The Orsiro Coronary Drug-Eluting Stent (DES) by BIOTRONIK, with its Ultrathin Strut design, set a new clinical benchmark for cardiovascular treatments. The final 5-year data from the BIOFLOW-V trial reinforced the stent's superior safety profile, confirming Orsiro's status as a gold standard in DES technology. This study further supports the use of Orsiro as a reliable, long-term solution for coronary artery disease
• In March 2021, Meril Life Sciences launched its indigenously developed MeRes100, a bioresorbable scaffold stent. The MeRes100 is a thin-struct bioresorbable stent designed as an alternative to traditional metallic stents. This innovative product offers a promising treatment option by gradually dissolving within the body, reducing long-term complications and the need for further interventions, while still providing adequate support during the healing process for patients with coronary artery disease
• In October 2021, Boston Scientific Corporation unveiled positive results for its Eluvia Drug-Eluting Vascular Stent System at the Vascular InterVentional Advances conference in Las Vegas. The stent system demonstrated impressive clinical outcomes, with higher sustained clinical improvement and superior primary patency rates. This late-breaking trial presentation highlighted the effectiveness of Eluvia in providing long-term vascular support, making it a leading option for treating peripheral artery disease with promising patient outcomes

SKU-47808